Clinical Trials
Braintumor Website

 For People with Newly Diagnosed Glioblastoma Multiforme
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM)
With Epidermal Growth Factor Receptor (EGFR) Amplification

 For People with Reccurent Glioblastoma Multiforme (and other malignant gliomas)
A Study of ABT-414 in Adult or Pediatric Subjects With Recurrent Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
Neuroblate MRI-Guided Laser Surgery for recurrent GBM.
Aldoxorubicin Trial for recurrent GBM.

These trials were the most recently added or updated

NCT Trial Name# of CentersLast Updated

NCT03058289

  A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
304/06/2017

NCT02851706

  Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
104/06/2017

NCT02455557

  SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
504/06/2017

NCT02133183

  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
704/06/2017

NCT01502917

  Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
104/06/2017

NCT01326104

  Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
304/06/2017

NCT02617589

  An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
12104/05/2017

NCT02520882

  68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas
104/05/2017

NCT01801371

  68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
104/05/2017

NCT01356290

  Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma
1204/05/2017

NCT02992964

  Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
104/04/2017

NCT02945826

  uPAR-PET/MRI in Glioblastoma Multiforme
104/04/2017

NCT02780804

  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
1904/04/2017

NCT02764151

  First in Patient Study for PF-06840003 in Malignant Gliomas
1504/04/2017

NCT02667587

  An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
11804/04/2017

NCT02546102

  Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
6404/04/2017

NCT02311920

  Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
1004/04/2017

NCT02308020

  A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
4904/04/2017

NCT02271711

  Fourth Ventricle Infusions of Autologous Ex Vivo Expanded NK Cells in Children With Recurrent Posterior Fossa Tumors
104/04/2017

NCT02142803

  TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
204/04/2017

NCT02095132

  WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
1904/04/2017

NCT01849146

  WEE1 Inhibitor AZD1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
404/04/2017

NCT01770353

  Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent
404/04/2017

NCT01622868

  Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
10304/04/2017

NCT03075514

  Ketogenic Diets as an Adjuvant Therapy in Glioblastoma
104/03/2017

NCT03033706

  Intraoperative Goal Directed Fluid Management in Supratentorial Brain Tumor Craniotomy
104/03/2017

NCT02971319

  Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma
904/03/2017

NCT02831959

  Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
2404/03/2017

NCT02478164

  Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
204/03/2017

NCT02359565

  Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, or Hypermutated Brain Tumors
304/03/2017

NCT02255461

  Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
1104/03/2017

NCT02029690

  Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
104/03/2017

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
1304/03/2017

NCT02997423

  Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
1803/31/2017

NCT01644773

  Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
103/31/2017

NCT00897286

  Study of Stored Tumor Samples in Young Patients With Brain Tumors
103/31/2017

NCT03102203

  Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging
103/30/2017

NCT03101813

  International Diffuse Intrinsic Pontine Glioma (DIPG) Registry and Repository
103/30/2017

NCT02661282

  Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients
103/30/2017

NCT02234050

  Trabectedin for Recurrent Grade II/III Meningioma
4703/30/2017

NCT02223052

  Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
903/30/2017

NCT01878617

  A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
1803/30/2017

NCT00602667

  Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
603/30/2017

NCT02864368

  Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
103/29/2017

NCT02792582

  A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
103/29/2017

NCT02500459

  Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
103/29/2017

NCT02358187

  A Vaccine Trial for Low Grade Gliomas
103/29/2017

NCT02208362

  Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
103/29/2017

NCT01925573

  Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
103/29/2017

NCT01130077

  A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
103/29/2017



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites